Mapracorat Ophthalmic Suspension 3%
Drug timelines are a Plus or Pro feature.
4 regulatory and trial events tracked for Mapracorat Ophthalmic Suspension 3%, covering 2013-11-26 to 2020-09-03. Get the full timeline:
Most recent: Clinical Trial Update: Mapracorat Ophthalmic Suspension, 3% for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery [Phase 3]